CD8A and hepatocellular carcinoma: In this study, we first found that after lenvatinib therapy, the frequency of CD8+ T cytotoxic cells in peripheral blood of patients with HCC had continuously and significantly increased; meanwhile, those patients with higher CTL cells appeared to achieve better clinical response and OS.